MX2018014033A - Nuevos derivados de bencimidazol como ligandos de histamina h1 dual y receptor de histamina h4. - Google Patents

Nuevos derivados de bencimidazol como ligandos de histamina h1 dual y receptor de histamina h4.

Info

Publication number
MX2018014033A
MX2018014033A MX2018014033A MX2018014033A MX2018014033A MX 2018014033 A MX2018014033 A MX 2018014033A MX 2018014033 A MX2018014033 A MX 2018014033A MX 2018014033 A MX2018014033 A MX 2018014033A MX 2018014033 A MX2018014033 A MX 2018014033A
Authority
MX
Mexico
Prior art keywords
histamine
dual
receptor ligands
benzimidazole derivatives
derivatives
Prior art date
Application number
MX2018014033A
Other languages
English (en)
Inventor
Robert Philippe
Capet Marc
Levoin Nicolas
Ligneau Xavier
Schwartz Jean-Charles
Labeeuw Olivier
Berrebi-Bertrand Isabelle
Calmels Thierry
Billot Xavier
Krief Stéphane
Marie Lecomte Jeanne-
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MX2018014033A publication Critical patent/MX2018014033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se relaciona con nuevos derivados enantioméricos de bencimidazol, su proceso de preparación y sus usos terapéuticos como ligandos duales de receptores H1 y H4.
MX2018014033A 2017-11-15 2018-11-15 Nuevos derivados de bencimidazol como ligandos de histamina h1 dual y receptor de histamina h4. MX2018014033A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17306587 2017-11-15

Publications (1)

Publication Number Publication Date
MX2018014033A true MX2018014033A (es) 2019-06-10

Family

ID=60473453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014033A MX2018014033A (es) 2017-11-15 2018-11-15 Nuevos derivados de bencimidazol como ligandos de histamina h1 dual y receptor de histamina h4.

Country Status (22)

Country Link
US (2) US11306069B2 (es)
EP (1) EP3486243B1 (es)
JP (2) JP2019089761A (es)
KR (1) KR20190055775A (es)
CN (1) CN109824651A (es)
AU (1) AU2018264079B2 (es)
BR (1) BR102018073582A2 (es)
CA (1) CA3024429A1 (es)
CY (1) CY1123083T1 (es)
DK (1) DK3486243T3 (es)
ES (1) ES2807191T3 (es)
HR (1) HRP20200791T1 (es)
HU (1) HUE050735T2 (es)
IL (1) IL263063B (es)
LT (1) LT3486243T (es)
MX (1) MX2018014033A (es)
PL (1) PL3486243T3 (es)
PT (1) PT3486243T (es)
RS (1) RS60320B1 (es)
SI (1) SI3486243T1 (es)
TW (1) TWI787392B (es)
ZA (1) ZA201807674B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683191B2 (en) * 2000-06-05 2004-01-27 Ortho-Mcneil Pharmaceuticals, Inc. Method for synthesis of substituted azole libraries
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands

Also Published As

Publication number Publication date
CY1123083T1 (el) 2021-10-29
IL263063B (en) 2021-09-30
AU2018264079A1 (en) 2019-05-30
TWI787392B (zh) 2022-12-21
US20220281839A1 (en) 2022-09-08
BR102018073582A2 (pt) 2020-07-07
EP3486243B1 (en) 2020-04-15
TW201922727A (zh) 2019-06-16
AU2018264079B2 (en) 2022-06-30
US20190144421A1 (en) 2019-05-16
JP2023112012A (ja) 2023-08-10
ZA201807674B (en) 2019-09-25
PT3486243T (pt) 2020-06-22
RS60320B1 (sr) 2020-07-31
US11306069B2 (en) 2022-04-19
SI3486243T1 (sl) 2020-07-31
CA3024429A1 (en) 2019-05-15
LT3486243T (lt) 2020-07-27
JP2019089761A (ja) 2019-06-13
CN109824651A (zh) 2019-05-31
HRP20200791T1 (hr) 2020-07-24
HUE050735T2 (hu) 2021-01-28
DK3486243T3 (da) 2020-06-08
KR20190055775A (ko) 2019-05-23
ES2807191T3 (es) 2021-02-22
PL3486243T3 (pl) 2020-10-19
EP3486243A1 (en) 2019-05-22
IL263063A (en) 2019-03-31

Similar Documents

Publication Publication Date Title
IL288341B (en) Targeted ligands for medicinal compounds, methods for their preparation and uses thereof
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
MX2019013194A (es) Procedimientos para preparar compuestos de tipo oxatiazina.
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
PH12017501152A1 (en) Process for the preparation of a diarylthiohydantoin compound
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2020003369A (es) Enantiomeros de tiazoles sustituidos como compuestos antivirales.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
EP3284275A4 (en) PRE-PERSONALIZATION OF eSIMs TO SUPPORT LARGE-SCALE eSIM DELIVERY
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
IL290511A (en) Process for preparing 2-(phenylimino)-3-alkyl-1, 3-thiazolidin-4-ones
MX2018014033A (es) Nuevos derivados de bencimidazol como ligandos de histamina h1 dual y receptor de histamina h4.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
EP3638220A4 (en) PREPARATION OF (S, S
EP3564243A4 (en) METHOD FOR PRODUCTION OF ERIBULIN MESYLATE AND METHOD FOR PRODUCTION THEREOF
EP3878455A4 (en) USE OF 3-O-SULFAMOYLOXY-7SS-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETRAEN-17A-ONE IN THE TREATMENT OF BREAST CANCER
MX2018012237A (es) Procesos para preparar compuestos similares a la oxatiacina.
EP3677675A4 (en) FRUCTOSE-4-EPIMERASE AND METHOD FOR MANUFACTURING TAGATOSE USING THE SAME
AU2017904453A0 (en) Process for preparing 2-substituted 3',4'-polyhydroxystilbene compounds
AU2016902835A0 (en) Methods of treatment of cancer, using gold(i)-gold(iii) complexes